Sygnature Discovery announced a new addition to its leadership team, with the appointment of industry veteran Jade Dagher as General Manager for Canada.
Jade has over 35 years of experience in pharmaceuticals, including 25 years with Merck. He is fluent in English, French, and Arabic, and holds an MBA in strategic management and finance from McGill University CA, as well as a bachelor's degree in biochemistry.
In his new role, he will be responsible for the commercial leadership of Sygnature’s operations in Canada, building on its successful acquisition of NuChem Sciences in 2023, one of North America’s largest discovery contract research organizations.
Prior to joining the team at Sygnature Discovery, Jade served as General Manager in Northwestern Europe and Canada for Roche Diabetes Care, one of the world’s leading pharmaceutical companies. In this role, he was the driving force behind the strategic planning and implementation of the company’s Canadian operations, as well as managing a team of over 200 employees across 11 markets.
His earlier experience at Merck involved leading the Primary Care & Vaccines portfolio, a major part of the Canadian business unit, with revenues nearing $500M. Jade held a variety of leadership roles with the company, including Vice President of Market Access, Vice President of Sales and Marketing, Primary Care & Vaccines, Director of Marketing, Vaccines and Director of Marketing, Infectious Diseases, Oncology & Hospital Acute Care.
He brings an in-depth knowledge of the Canadian market and global senior leadership to his new role at Sygnature Discovery.
Commenting on his new appointment Jade said: “I was attracted to this role by the opportunity of building Sygnature Discovery’s North American presence, following its recent major expansion into the Canadian market. Throughout my career, I have run new operating models to maximize synergies and profitability and led major transformations for some of the biggest names in the business. I have a strong background in regulatory affairs, market access, sales, marketing, and health management that I bring to my new position with Sygnature Discovery”.
CEO at Sygnature Discovery Dr Simon Hirst added: “Jade is an experienced and accomplished global commercial leader, with demonstrable results across different cultures, markets, and functions in the pharmaceutical, vaccines, and medtech industries. His strategic leadership skills, strong collaborative spirit, and passion for talent development make him an ideal candidate for this role. Jade is a versatile and resilient, clear communicator able to empower diverse teams to achieve commercial success, and will be crucial to taking our North American operations to the next level.”